|  | | 
 | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | |
|
| | | 
| |  | |
News Hub Callendar
| < January 2009 | | Su | M | T | W | T | F | S | | | 1 | 2 | 3 |
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
|
| |
|
| | Novo Nordisk Prevails in Sanofi-Aventis Challenge to Levemir® |
|
date: Jul 4th 2006 11:49
page: 1 | 2
Up to 24 Hours Duration of Action and Other Claims Upheld.
Novo Nordisk announced today a victory in a lawsuit in which Sanofi-Aventis sought a preliminary injunction against Novo Nordisk s pre-launch and launch materials for Levemir® (insulin detemir [rDNA origin] injection), Novo Nordisk s new long-acting basal insulin.
The lawsuit, filed in United States District Court for the District of New Jersey by Sanofi-Aventis, alleges that Novo Nordisk engaged in false advertising in pre-launch and launch materials for Levemir. However, during the court hearing on April 11, Sanofi-Aventis dropped its attack on the launch materials. Ruling on the remaining claims about the pre-launch materials, Judge Mary Cooper found that there was no reasonable probability of success on the merits of Sanofi-Aventis s claims in the lawsuit.
On March 27th, Novo Nordisk launched the long-acting basal insulin analog Levemir and Levemir FlexPen® for the treatment of type 1 and type 2 diabetes. Levemir is proven to help patients reach glycemic targets with up to 24 hours of control, and has demonstrated low rates of hypoglycemia, less weight gain than NPH and consistent blood glucose response. Specifically, the 56-page opinion rejected challenges to Novo Nordisk s statements that Levemir:
- Works for up to 24 hours
- Can be used once daily
- Causes less weight gain than NPH insulin and
- Consistent blood glucose response.
We are pleased with this court action, and are confident that the ultimate outcome of this litigation will support our position on this issue. It is unfortunate this lawsuit is diverting attention from the real issue — ensuring patients have access to individualized treatment options, said Martin Soeters, president of Novo Nordisk. Novo Nordisk is committed to alleviating the burden of diabetes, working as a catalyst to advance care through innovation, awareness, and education. We believe our recent launch of Levemir and Levemir FlexPen offer important treatment options for people living with uncontrolled diabetes.
page: 1 | 2
article 'Novo Nordisk Prevails in Sanofi-Aventis Challenge to Levemir®' source is Novo Nordisk US, visit source site:
Articles by information source
News and articles by category
News and articles by day |
|
